Experimental toxicology of ASTA Z 7557 (INN mafosfamide) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1984-06

AUTHORS

Joerg Pohl, Peter Hilgard, Wolfgang Jahn, Hans-Juergen Zechel

ABSTRACT

The LD 50 of Z 7557 in mice was between 500 and 625 mg/kg after i.v. and around 2310 mg/kg after oral administration. The corresponding LD 10 was around 435 mg/kg (i.v.) or 1100-1250 mg/kg (p.o.), respectively. The LD 50 values in rats were in the range of 250-310 mg/kg after i.v. administration and around 1000-1250 mg/kg if given orally. With repeated daily i.v. injections only 70% of the daily dose contributed to lethality. A second administration of Z 7557 to rats after reversal of all toxic signs from the first administration induced the same symptoms and degree of toxicity as the initial injection. Reversible myelosuppression was the predominant feature of toxicity in mice and rats, but at equimolar doses this myelotoxicity was less than half that of cyclophosphamide (CP). First signs of immunosuppression were seen only at 100 mg/kg i.v.. No severe urotoxicity was observed in rats with single i.v. doses up to 192 mg/kg. This might be due to the fast and complete renal excretion of the thiol moiety of Z 7557, whereas the activated oxazaphosphorine component occurred in the urine only to a much smaller amount, as could be shown by a pilot pharmacokinetic study. In conclusion, Z 7557 appeared to have an overall tolerance in rats and mice similar to cyclophosphamide but was clearly less toxic with respect to the bone marrow, the immune system and the urinary tract. More... »

PAGES

201-206

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00232352

DOI

http://dx.doi.org/10.1007/bf00232352

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023463040

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/6469515


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibody Formation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lethal Dose 50", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organ Size", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Inbred Strains", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pohl", 
        "givenName": "Joerg", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hilgard", 
        "givenName": "Peter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jahn", 
        "givenName": "Wolfgang", 
        "id": "sg:person.0672360256.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672360256.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zechel", 
        "givenName": "Hans-Juergen", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00284124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013128331", 
          "https://doi.org/10.1007/bf00284124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00284124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013128331", 
          "https://doi.org/10.1007/bf00284124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0046-8177(74)80028-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017917668"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00964578", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025565295", 
          "https://doi.org/10.1007/bf00964578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(82)90143-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033699183"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2964(81)90261-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042755367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075292450", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080302842", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082206891", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1984-06", 
    "datePublishedReg": "1984-06-01", 
    "description": "The LD 50 of Z 7557 in mice was between 500 and 625 mg/kg after i.v. and around 2310 mg/kg after oral administration. The corresponding LD 10 was around 435 mg/kg (i.v.) or 1100-1250 mg/kg (p.o.), respectively. The LD 50 values in rats were in the range of 250-310 mg/kg after i.v. administration and around 1000-1250 mg/kg if given orally. With repeated daily i.v. injections only 70% of the daily dose contributed to lethality. A second administration of Z 7557 to rats after reversal of all toxic signs from the first administration induced the same symptoms and degree of toxicity as the initial injection. Reversible myelosuppression was the predominant feature of toxicity in mice and rats, but at equimolar doses this myelotoxicity was less than half that of cyclophosphamide (CP). First signs of immunosuppression were seen only at 100 mg/kg i.v.. No severe urotoxicity was observed in rats with single i.v. doses up to 192 mg/kg. This might be due to the fast and complete renal excretion of the thiol moiety of Z 7557, whereas the activated oxazaphosphorine component occurred in the urine only to a much smaller amount, as could be shown by a pilot pharmacokinetic study. In conclusion, Z 7557 appeared to have an overall tolerance in rats and mice similar to cyclophosphamide but was clearly less toxic with respect to the bone marrow, the immune system and the urinary tract.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00232352", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "name": "Experimental toxicology of ASTA Z 7557 (INN mafosfamide)", 
    "pagination": "201-206", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00232352"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6fc8dac888e022b34fd210a883396fe0d63458355fa472e93ece719f7e0e1a03"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023463040"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "6469515"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00232352", 
      "https://app.dimensions.ai/details/publication/pub.1023463040"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91444_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00232352"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00232352'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00232352'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00232352'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00232352'


 

This table displays all metadata directly associated to this object as RDF triples.

159 TRIPLES      21 PREDICATES      48 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00232352 schema:about N102082a796df4bafa5d2f210cdc82dbe
2 N3aebb98929594aa7892eea80bd1c0232
3 N6a5ba96c44fa4e269d28a3ac418236e5
4 N6f9d6c6bb0704866859dcb2a466467cf
5 N7f6027f2ba364748a51a521d07059894
6 Na60de46dbd37453c83ee40b28c223f88
7 Nafcbc2885c9e4d90977ef90f4e4e61c8
8 Nbcf9402def404dddbcd1d8dbbfd43e81
9 Nc1443bf8b8ee45c4a3de3d314711ca0f
10 Nc841291c13094f7dad423e08fdc5ebc7
11 Ne5a4b90748f14e34abdc24c0c2115f66
12 anzsrc-for:11
13 anzsrc-for:1115
14 schema:author Na86caf1bb096424883417c315797f4af
15 schema:citation sg:pub.10.1007/bf00284124
16 sg:pub.10.1007/bf00964578
17 https://app.dimensions.ai/details/publication/pub.1075292450
18 https://app.dimensions.ai/details/publication/pub.1080302842
19 https://app.dimensions.ai/details/publication/pub.1082206891
20 https://doi.org/10.1016/0014-2964(81)90261-9
21 https://doi.org/10.1016/0277-5379(82)90143-2
22 https://doi.org/10.1016/s0046-8177(74)80028-6
23 schema:datePublished 1984-06
24 schema:datePublishedReg 1984-06-01
25 schema:description The LD 50 of Z 7557 in mice was between 500 and 625 mg/kg after i.v. and around 2310 mg/kg after oral administration. The corresponding LD 10 was around 435 mg/kg (i.v.) or 1100-1250 mg/kg (p.o.), respectively. The LD 50 values in rats were in the range of 250-310 mg/kg after i.v. administration and around 1000-1250 mg/kg if given orally. With repeated daily i.v. injections only 70% of the daily dose contributed to lethality. A second administration of Z 7557 to rats after reversal of all toxic signs from the first administration induced the same symptoms and degree of toxicity as the initial injection. Reversible myelosuppression was the predominant feature of toxicity in mice and rats, but at equimolar doses this myelotoxicity was less than half that of cyclophosphamide (CP). First signs of immunosuppression were seen only at 100 mg/kg i.v.. No severe urotoxicity was observed in rats with single i.v. doses up to 192 mg/kg. This might be due to the fast and complete renal excretion of the thiol moiety of Z 7557, whereas the activated oxazaphosphorine component occurred in the urine only to a much smaller amount, as could be shown by a pilot pharmacokinetic study. In conclusion, Z 7557 appeared to have an overall tolerance in rats and mice similar to cyclophosphamide but was clearly less toxic with respect to the bone marrow, the immune system and the urinary tract.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf Nb115648073154f768b0b73b0aed8cf1f
30 Nf4ab1a1186224115890b7ff8ebc0ea4a
31 sg:journal.1094201
32 schema:name Experimental toxicology of ASTA Z 7557 (INN mafosfamide)
33 schema:pagination 201-206
34 schema:productId N483f7b370e234d5eb85edabd0b09d467
35 N83d84da8226b4841a9c8f5d9cd336359
36 N973c1123be654996bd4aab006d4bbe85
37 Nd3aeb42a4e024386b0d9dbabec0148ed
38 Ne3c840c079b746579cef26612c8d302e
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023463040
40 https://doi.org/10.1007/bf00232352
41 schema:sdDatePublished 2019-04-15T09:01
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher Nba628156825f4b93b60c24a120ee725f
44 schema:url http://link.springer.com/10.1007/BF00232352
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N088577b5a8e6467c8d065458c9fa6a42 rdf:first Ne37b7121c33a494e810981f3e5ab6015
49 rdf:rest N21e68b80fecf4680a85464cd7d3f3622
50 N102082a796df4bafa5d2f210cdc82dbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Animals
52 rdf:type schema:DefinedTerm
53 N108377ef1b4347a9b34d6ab973ffd516 schema:name Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany
54 rdf:type schema:Organization
55 N21e68b80fecf4680a85464cd7d3f3622 rdf:first sg:person.0672360256.43
56 rdf:rest N46e8f19b606d4d7cbe4dd6610c91ae82
57 N3301678314974ba9ba8021830b5d4a0f schema:name Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany
58 rdf:type schema:Organization
59 N3aebb98929594aa7892eea80bd1c0232 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Organ Size
61 rdf:type schema:DefinedTerm
62 N403f7e998b5948f8995cdf78d685207b schema:name Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany
63 rdf:type schema:Organization
64 N46e8f19b606d4d7cbe4dd6610c91ae82 rdf:first Nc86604f12c8445b78adbfb5ad5f2bdb2
65 rdf:rest rdf:nil
66 N483f7b370e234d5eb85edabd0b09d467 schema:name nlm_unique_id
67 schema:value 8309330
68 rdf:type schema:PropertyValue
69 N6a5ba96c44fa4e269d28a3ac418236e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Antibody Formation
71 rdf:type schema:DefinedTerm
72 N6f9d6c6bb0704866859dcb2a466467cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Kinetics
74 rdf:type schema:DefinedTerm
75 N7f6027f2ba364748a51a521d07059894 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Rats, Inbred Strains
77 rdf:type schema:DefinedTerm
78 N83d84da8226b4841a9c8f5d9cd336359 schema:name doi
79 schema:value 10.1007/bf00232352
80 rdf:type schema:PropertyValue
81 N973c1123be654996bd4aab006d4bbe85 schema:name pubmed_id
82 schema:value 6469515
83 rdf:type schema:PropertyValue
84 Na60de46dbd37453c83ee40b28c223f88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Lethal Dose 50
86 rdf:type schema:DefinedTerm
87 Na86caf1bb096424883417c315797f4af rdf:first Nb4bb6b468eed4ad1bc1c43e972b9f4d5
88 rdf:rest N088577b5a8e6467c8d065458c9fa6a42
89 Nafcbc2885c9e4d90977ef90f4e4e61c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Rats
91 rdf:type schema:DefinedTerm
92 Nb115648073154f768b0b73b0aed8cf1f schema:volumeNumber 2
93 rdf:type schema:PublicationVolume
94 Nb4bb6b468eed4ad1bc1c43e972b9f4d5 schema:affiliation N3301678314974ba9ba8021830b5d4a0f
95 schema:familyName Pohl
96 schema:givenName Joerg
97 rdf:type schema:Person
98 Nba628156825f4b93b60c24a120ee725f schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 Nbcf9402def404dddbcd1d8dbbfd43e81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Cyclophosphamide
102 rdf:type schema:DefinedTerm
103 Nc1443bf8b8ee45c4a3de3d314711ca0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Bone Marrow
105 rdf:type schema:DefinedTerm
106 Nc841291c13094f7dad423e08fdc5ebc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Urinary Bladder
108 rdf:type schema:DefinedTerm
109 Nc86604f12c8445b78adbfb5ad5f2bdb2 schema:affiliation N403f7e998b5948f8995cdf78d685207b
110 schema:familyName Zechel
111 schema:givenName Hans-Juergen
112 rdf:type schema:Person
113 Nd3aeb42a4e024386b0d9dbabec0148ed schema:name readcube_id
114 schema:value 6fc8dac888e022b34fd210a883396fe0d63458355fa472e93ece719f7e0e1a03
115 rdf:type schema:PropertyValue
116 Nd9f9cc9c38434a6d8d611efb76a4c088 schema:name Department of Experimental Cancer Research and Toxicological Institute, Asta-Werke AG, Degussa Pharma Gruppe, Bielefeld, Germany
117 rdf:type schema:Organization
118 Ne37b7121c33a494e810981f3e5ab6015 schema:affiliation N108377ef1b4347a9b34d6ab973ffd516
119 schema:familyName Hilgard
120 schema:givenName Peter
121 rdf:type schema:Person
122 Ne3c840c079b746579cef26612c8d302e schema:name dimensions_id
123 schema:value pub.1023463040
124 rdf:type schema:PropertyValue
125 Ne5a4b90748f14e34abdc24c0c2115f66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Mice
127 rdf:type schema:DefinedTerm
128 Nf4ab1a1186224115890b7ff8ebc0ea4a schema:issueNumber 2
129 rdf:type schema:PublicationIssue
130 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
131 schema:name Medical and Health Sciences
132 rdf:type schema:DefinedTerm
133 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
134 schema:name Pharmacology and Pharmaceutical Sciences
135 rdf:type schema:DefinedTerm
136 sg:journal.1094201 schema:issn 0167-6997
137 1573-0646
138 schema:name Investigational New Drugs
139 rdf:type schema:Periodical
140 sg:person.0672360256.43 schema:affiliation Nd9f9cc9c38434a6d8d611efb76a4c088
141 schema:familyName Jahn
142 schema:givenName Wolfgang
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672360256.43
144 rdf:type schema:Person
145 sg:pub.10.1007/bf00284124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013128331
146 https://doi.org/10.1007/bf00284124
147 rdf:type schema:CreativeWork
148 sg:pub.10.1007/bf00964578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025565295
149 https://doi.org/10.1007/bf00964578
150 rdf:type schema:CreativeWork
151 https://app.dimensions.ai/details/publication/pub.1075292450 schema:CreativeWork
152 https://app.dimensions.ai/details/publication/pub.1080302842 schema:CreativeWork
153 https://app.dimensions.ai/details/publication/pub.1082206891 schema:CreativeWork
154 https://doi.org/10.1016/0014-2964(81)90261-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042755367
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/0277-5379(82)90143-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033699183
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/s0046-8177(74)80028-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017917668
159 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...